Faruqi and Faruqui, LLP Logo
Share this page

Kitov Pharmaceutical Holdings Ltd. (KTOV)

NASDAQ: KTOV

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Kitov Pharmaceutical Holdings Ltd. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Kitov Pharmaceutical Holdings Ltd. (“Kitov” or the “Company”) (NASDAQ: KTOV).

The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that some of its executives might have been involved in publishing false information.

Specifically, on February 6, 2017, the Israeli publication Calcalist reported that Kitov’s chief executive officer, Isaac Israel, had been detained and questioned by the Israeli Securities Authority.  Citing court documents, the publication also stated that the Company might have published misleading information regarding findings from an independent committee appointed to check clinical trial results of one of the Company’s drugs.

Take Action

If you invested in Kitov stock or options and would like to discuss your legal rights, please fill out the form below.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Kitov’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Kitov Pharmaceutical Holdings Ltd. (KTOV)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 02/07/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.